• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy

    6/22/26 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $CVS alert in real time by email

    New $50 monthly copay for eligible Medicare patients, one-on-one pharmacist guidance, and over-the-counter products to help manage common side effects available to support patients 

    MinuteClinic® expands virtual care with new weight management offering and $49 visits

    WOONSOCKET, R.I., June 22, 2026 /PRNewswire/ -- As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today announced a comprehensive approach to GLP-1 support spanning its more than 9,000 CVS Pharmacy® locations and MinuteClinic®, available virtually in nearly all states. New offerings include expanded pharmacy support designed to help patients access these treatments and stay on them, and a new $49 MinuteClinic virtual visit that connects eligible adults with licensed clinicians who can evaluate and, where clinically appropriate, prescribe GLP-1 therapy.

    CVS pharmacist consulting with patient.

    The new approach combines lower-cost access, personalized pharmacist support, and over-the-counter products to help manage common side effects, which are three of the biggest barriers patients face when starting GLP‑1 therapy.

    CVS Pharmacy offers a broad range of GLP‑1 prescription medications, including both injectable and oral options from multiple manufacturers, along with new digital resources available on CVS.com. Together with guidance from trusted neighborhood pharmacists, these tools are designed to support patients from their first dose through ongoing treatment.

    "Access is only part of the equation with GLP‑1 medications. Patients also need support to stay on therapy and see results," said Sid Tenneti, Senior Vice President and Interim President, Pharmacy and Consumer Wellness. "From helping patients manage side effects to identifying ways to lower costs, our pharmacists are there every step of the way."

    Lower cost access to GLP-1 medications

    To help address cost concerns, CVS Pharmacy will begin participating in the Centers for Medicare & Medicaid Services (CMS) Medicare GLP‑1 Bridge program starting July 1, 2026. Through the program, which runs through December 31, 2027, eligible Medicare beneficiaries can access certain GLP‑1 medications for $50 per month, offering more predictable and affordable pricing for patients who qualify.

    For those not eligible, CVS Pharmacy accepts a wide range of third-party prescription discount cards, manufacturer coupons, and manufacturer vouchers to help reduce out-of-pocket costs. At CVS Pharmacy, the out-of-pocket cost for a GLP-1 medication can be as low as $25 a month through commercial insurance with a manufacturer coupon for eligible patients, or $149 for those without insurance who utilize a manufacturer voucher for qualifying medications and doses. CVS Pharmacy is a retail pharmacy partner for NovoCare®, a program that offers discounted Wegovy® and Ozempic®, and was the first to build a streamlined NovoCare enrollment experience.

    Pharmacists at the center of care

    As more patients turn to GLP‑1 medications, CVS Pharmacy is emphasizing the role of its pharmacists in helping patients navigate treatment.

    According to the CVS Health 2025 Rx Report, nearly half of consumers prioritize personalized care at the pharmacy, and many prefer in-person pharmacy support over digital-only options - highlighting the ongoing importance of face-to-face interactions with pharmacists. From answering questions about dosing to helping patients manage side effects and stay on track, CVS pharmacists play a critical role in supporting the overall treatment experience and are available when it is convenient for the patient.

    Clinical weight loss support available at MinuteClinic

    MinuteClinic is broadening its virtual care platform with the launch of a new digital health offering that connects eligible adults with licensed clinicians to evaluate their weight loss and metabolic health needs and, where clinically appropriate, prescribe FDA-approved GLP-1 medications for weight loss.

    At $49 per visit with no recurring membership or monthly fee, the program is built to make a first step toward weight management straightforward and affordable. Patients begin with a virtual video visit with a licensed physician associate or nurse practitioner, who reviews their health history and weight-management goals before determining whether a GLP-1 therapy is the right fit. Those who start treatment can schedule follow-up visits as needed for dose adjustments, side-effect support, and ongoing monitoring.

    The program is available in 47 states and Washington, D.C., and is designed for self-pay adults ages 18 to 64 who are overweight or living with obesity and intend to pay out of pocket for clinical weight loss services. Patients seeking weight loss or metabolic health clinical support can visit MinuteClinic.com.

    Over-the-counter products to help manage side effects

    Side effects remain one of the leading reasons patients discontinue GLP‑1 therapy. To help address this, CVS Pharmacy has expanded its product assortment and is highlighting CVS brand and national brand over-the-counter products to help make managing side effects easier. Pharmacists can discuss concerns and help manage side effects in collaboration with prescribers.

    In select locations, dedicated product displays highlight items that can help manage common issues such as nausea and gastrointestinal discomfort, as well as products that support hydration, protein intake, and overall nutrition. These in-store curated displays, sponsored by Haleon, are designed to bring together pharmacist guidance and practical, easy-to-find products to make it simpler for patients to manage their treatment. 

    Customers can also select from a wide array of CVS brand products found throughout the store to help manage common GLP-1 side effects that offer the quality and value customers have come to expect from CVS Pharmacy store brands.

    For more information on CVS Pharmacy's GLP‑1 support offerings, visit www.CVS.com/GLP1.

    *For weight loss-related consultation only. Does not include the price of laboratory tests required.

    About CVS Health

    CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

    Media contact

    Amy Thibault

    401-318-2865

    Amy.Thibault@CVSHealth.com

    CVS Health (PRNewsFoto/CVS Health)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-pharmacy-expands-glp1-support-to-lower-costs-improve-access-and-help-patients-stay-on-therapy-302805691.html

    SOURCE CVS Health

    Get the next $CVS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CVS

    DatePrice TargetRatingAnalyst
    3/12/2026$94.00Mkt Perform → Outperform
    Bernstein
    10/14/2025$91.00Buy
    Goldman
    8/18/2025$79.00Neutral → Buy
    UBS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$55.00 → $75.00Market Perform → Outperform
    Leerink Partners
    2/12/2025Neutral → Overweight
    Cantor Fitzgerald
    1/30/2025Hold → Buy
    Edward Jones
    12/3/2024$66.00Hold → Buy
    Deutsche Bank
    More analyst ratings

    $CVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    CVS Health upgraded by Bernstein with a new price target

    Bernstein upgraded CVS Health from Mkt Perform to Outperform and set a new price target of $94.00

    3/12/26 8:38:26 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health upgraded by UBS with a new price target

    UBS upgraded CVS Health from Neutral to Buy and set a new price target of $79.00

    8/18/25 8:45:28 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CVS Pharmacy® expands GLP‑1 support to lower costs, improve access, and help patients stay on therapy

    New $50 monthly copay for eligible Medicare patients, one-on-one pharmacist guidance, and over-the-counter products to help manage common side effects available to support patients MinuteClinic® expands virtual care with new weight management offering and $49 visitsWOONSOCKET, R.I., June 22, 2026 /PRNewswire/ -- As demand for GLP-1 medications continues to increase across the U.S., CVS Health® (NYSE:CVS) today announced a comprehensive approach to GLP-1 support spanning its more than 9,000 CVS Pharmacy® locations and MinuteClinic®, available virtually in nearly all states. New offerings include expanded pharmacy support designed to help patients access these treatments and stay on them, and

    6/22/26 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.)Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary of Ae

    6/5/26 4:35:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health recognized for technology that improves medication safety and patient care

    The company was awarded a 2026 Newsweek AI Impact AwardWOONSOCKET, R.I., May 29, 2026 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced it has been recognized by Newsweek with the 2026 AI Impact Award in the AI Health Care category, specifically for Best Outcomes – Patient Care. The award recognizes CVS Health's AI-Driven Prescription Interpretation and Instruction Standardization technology, which embeds artificial intelligence directly into pharmacy dispensing workflows to help pharmacists improve medication safety and patient care across the company's national pharmacy network. "This recognition reflects our commitment

    5/29/26 8:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    SEC Filings

    View All

    SEC Form 11-K filed by CVS Health Corporation

    11-K - CVS HEALTH Corp (0000064803) (Filer)

    6/23/26 4:59:46 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form S-8 filed by CVS Health Corporation

    S-8 - CVS HEALTH Corp (0000064803) (Filer)

    5/22/26 4:28:36 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form S-3ASR filed by CVS Health Corporation

    S-3ASR - CVS HEALTH Corp (0000064803) (Filer)

    5/22/26 4:27:23 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financial Officer Newman Brian covered exercise/tax liability with 2,478 shares, decreasing direct ownership by 45% to 3,008 units (SEC Form 4) (withholding obligation)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/1/26 5:02:36 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP, Chief Medical Officer Compton-Phillips Amy covered exercise/tax liability with 7,618 shares, decreasing direct ownership by 44% to 9,557 units (SEC Form 4) (tax withholding)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/1/26 5:00:41 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Aguirre Fernando returned $3,000,372 worth of shares to the company (32,000 units at $93.76), decreasing direct ownership by 75% to 10,513 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    5/22/26 5:39:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Aetna 2026 Medicare Advantage plans deliver access to affordable, personalized care

    Providing access to affordable care $0 copays on Tier 1 drugs & covered vaccines at in-network pharmacies1, $0 copay for colonoscopies and mammograms at in-network providers$0 copay for annual Healthy Home Visit from a licensed Signify Health clinicianContinued investment in technology, tools and teams that support our members Commitment to supporting unique member needs — those living with chronic conditions and individuals dually eligible for both Medicare and MedicaidLeveraging the strength of the CVS Health family of companies to deliver differentiated member experiencesWOONSOCKET, R.I., Oct. 1, 2025 /PRNewswire/ -- Aetna®, a CVS Health® company (NYSE: CVS), today announced our 2026 Medi

    10/1/25 7:00:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

    WOONSOCKET, R.I., April 8, 2025 /PRNewswire/ -- CVS Health® (NYSE:CVS) today announced two leadership updates. Brian Newman has been named executive vice president and chief financial officer designate, effective April 21. He will succeed current chief financial officer, Tom Cowhey, who will transition to serve as a strategic advisor to president and chief executive officer David Joyner, effective May 12.Amy Compton-Phillips, M.D., is the company's new executive vice president and chief medical officer, effective May 19, also reporting to David Joyner.Based on year-to-date res

    4/8/25 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Financials

    Live finance-specific insights

    View All

    AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) of Aetna Life Insurance Company (ALIC) (Hartford, CT) and the other members of Aetna Health & Life Group, which are operating entities of Aetna Inc. (Aetna) and wholly owned subsidiaries of its ultimate parent, CVS Health Corporation (CVS Health) (NYSE:CVS). (Please see below for a detailed listing of the companies.)Concurrently, AM Best has affirmed the FSR of A (Excellent) and the Long-Term ICR of "a" (Excellent) of Allina Health and Aetna Insurance Company (Allina Health) (St. Louis Park, MN). Allina Health is a joint venture subsidiary of Ae

    6/5/26 4:35:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    ARCTRUST Acquires Seven Property Net Lease Portfolio for Planned DST Offering

    Diversified portfolio of Pinnacle Bank, CVS Pharmacy, and NAPA Auto Parts properties expands ARCTRUST's net lease platform for 1031 exchange investors ARCTRUST Private Capital, the capital markets division of the ARCTRUST Group of Companies, announced today the acquisition of a seven property, single-tenant net lease portfolio comprised of two Pinnacle Bank locations, three CVS Pharmacy locations, and two NAPA Auto Parts locations across six states. The portfolio will be offered to accredited investors as a Delaware statutory trust (DST): ARCTRUST Exchange II DST. The seven property portfolio consists of approximately 51,192 net rentable square feet across a combined land area of around

    5/28/26 8:00:00 AM ET
    $CVS
    $GPC
    $PNFP
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Automotive Aftermarket
    Consumer Discretionary

    CVS HEALTH CORPORATION REPORTS STRONG FIRST QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE

    First quarter total revenues increased to $100.4 billion, up 6.2% year-over-yearFirst quarter GAAP diluted EPS of $2.30 and Adjusted EPS of $2.57Raising full-year 2026 guidance:GAAP diluted EPS guidance range to $6.24 to $6.44 from $5.94 to $6.14Adjusted EPS guidance range to $7.30 to $7.50 from $7.00 to $7.20Cash flow from operations guidance to at least $9.5 billion from at least $9.0 billionWOONSOCKET, R.I., May 6, 2026 /PRNewswire/ -- CVS Health Corporation (NYSE:CVS) today announced operating results for the three months ended March 31, 2026."CVS Health continues to provide what people want most from health care: a connected, convenient, cost-effective engagement experience across our u

    5/6/26 6:30:00 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $CVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/13/24 5:02:40 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G/A filed by CVS Health Corporation (Amendment)

    SC 13G/A - CVS HEALTH Corp (0000064803) (Subject)

    2/9/23 11:16:32 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples